Randomized phase 2 trial of gefitinib with and without pemetrexed as first-line therapy in East Asian patients with advanced, epidermal growth factor receptor (EGFR) mutation-positive (mt plus ), nonsquamous (NS) non-small cell lung cancer (NSCLC): Translational research and interim overall survival (OS)

被引：0

作者：

Yang, J. ^{[1
]}

Cheng, Y. ^{[2
]}

Murakami, H. ^{[3
]}

Yang, P-C. ^{[1
]}

He, J. ^{[4
]}

Nakagawa, K. ^{[5
]}

Kang, J. H. ^{[6
]}

Kim, J-H. ^{[7
]}

Hozak, R. ^{[8
]}

Nguyen, T. ^{[9
]}

Wang, X. ^{[10
]}

Enatsu, S. ^{[11
]}

Puri, T. ^{[12
]}

Orlando, M. ^{[13
]}

机构：

[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[2] Jilin Prov Canc Hosp, Dept Med Oncol, Changchun, Peoples R China

[3] Shizuoka Canc Ctr, Dept Oncol, Shizuoka, Japan

[4] Guangzhou Med Univ, Affiliated Hosp 1, Dept Thorac Oncol, Guangzhou, Guangdong, Peoples R China

[5] Kindai Univ, Fac Med, Dept Med Oncol, Osaka, Japan

[6] Catholic Univ Korea, Dept Med Oncol, Seoel, South Korea

[7] CHA Univ, CHA Bundang Med Ctr, Dept Oncol, Gyeonggi Do, South Korea

[8] Eli Lilly & Co, Oncol Business Unit, Indianapolis, IN 46285 USA

[9] Eli Lilly & Co, Oncol Tailoring Biomarker Stat, Indianapolis, IN 46285 USA

[10] Eli Lilly & Co, Med Dev Unit, Shanghai, Peoples R China

[11] Eli Lilly Japan KK, Med Dev Unit, Kobe, Hyogo, Japan

[12] Eli Lilly & Co, Med Affairs, Gurgaon, India

[13] Eli Lilly & Co, Emerging Markets Med Affairs, Buenos Aires, Argentina

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw383.40

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1240P

引用

页数：1

共 50 条

[41] First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial [J].

Yang, James Chih-Hsin ;

Kang, Jin Hyoung ;

Mok, Tony ;

Ahn, Myung-Ju ;

Srimuninnimit, Vichien ;

Lin, Chia-Chi ;

Kim, Dong-Wan ;

Tsai, Chun-Ming ;

Barraclough, Helen ;

Altug, Sedat ;

Orlando, Mauro ;

Park, Keunchil .

EUROPEAN JOURNAL OF CANCER, 2014, 50 (13) :2219-2230

[42] Tumor epidermal growth factor receptor (EGFR) expression as a predictive biomarker of survival in FLEX study patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy plus cetuximab as first-line therapy [J].

von Pawel, J. ;

Eberhardt, W. E. E. ;

Reck, M. ;

Eschbach, C. ;

Fischer, J. R. ;

Schuette, W. ;

Bohnet, S. ;

Heeger, S. ;

Schumacher, K. -M. ;

von Heydebreck, A. ;

Pirker, R. .

ONKOLOGIE, 2011, 34 :121-121

[43] Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors [J].

Eric Nadler ;

Melissa Pavilack ;

Janet L. Espirito ;

Jamyia Clark ;

Ancilla Fernandes .

Advances in Therapy, 2020, 37 :946-954

[44] Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors [J].

Nadler, Eric ;

Pavilack, Melissa ;

Espirito, Janet L. ;

Clark, Jamyia ;

Fernandes, Ancilla .

ADVANCES IN THERAPY, 2020, 37 (02) :946-954

[45] Gefitinib plus Fuzheng Kang'ai Formula in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: A Randomized Controlled Trial [J].

Yang Xiao-bing ;

Chai Xiao-shu ;

Wu Wan-yin ;

Long Shun-qin ;

Deng Hong ;

Pan Zong-qi ;

He Wen-feng ;

Zhou Yu-shu ;

Liao Gui-ya ;

Xiao Shu-jing .

CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2018, 24 (10) :734-740

[46] First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Multicenter phase II trial (NEJ 003 study) [J].

Minegishi, Y. ;

Maemondo, M. ;

Okinaga, S. ;

Morikawa, N. ;

Inoue, A. ;

Kobayashi, K. ;

Harada, M. ;

Hagiwara, K. ;

Nukiwa, T. ;

Gemma, A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[47] Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer - data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002) [J].

Miyauchi, Eisaku ;

Inoue, Akira ;

Kobayashi, Kunihiko ;

Maemondo, Makoto ;

Sugawara, Shunichi ;

Oizumi, Satoshi ;

Isobe, Hiroshi ;

Gemma, Akihiko ;

Saijo, Yasuo ;

Yoshizawa, Hirohisa ;

Hagiwara, Koichi ;

Nukiwa, Toshihiro .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (07) :670-676

[48] Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR) [J].

Mitsudomi, Tetsuya ;

Morita, Satoshi ;

Yatabe, Yasushi ;

Negoro, Shunichi ;

Okamoto, Isamu ;

Seto, Takashi ;

Satouchi, Miyako ;

Tada, Hirohito ;

Hirashima, Tomonori ;

Asami, Kazuhiro ;

Katakami, Nobuyuki ;

Takada, Minoru ;

Yoshioka, Hiroshige ;

Shibata, Kazuhiko ;

Kudoh, Shinzoh ;

Shimizu, Eiji ;

Saito, Hiroshi ;

Toyooka, Shinichi ;

Nakagawa, Kazuhiko ;

Fukuoka, Masahiro .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

[49] Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence [J].

Ke, E-E ;

Wu, Yi-Long .

THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (03) :256-264

[50] Phase II study of gefitinib and inserted cisplatin plus docetaxel as a first-line treatment for advanced non-small cell lung cancer haboring an epidermal growth factor receptor activating mutation [J].

Kanda, Shintaro ;

Ohe, Yuichiro ;

Horinouchi, Hidehito ;

Fujiwara, Yutaka ;

Nokihara, Hiroshi ;

Yamamoto, Noboru ;

Sekine, Ikuo ;

Kunitoh, Hideo ;

Kubota, Kaoru ;

Tamura, Tomohide .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →